{"id":"full-course-of-pd-1blockades","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Fatigue"},{"rate":"15–25%","effect":"Diarrhea"},{"rate":"10–20%","effect":"Nausea"},{"rate":"3–5%","effect":"Immune-related pneumonitis"},{"rate":"2–5%","effect":"Immune-related hepatitis"},{"rate":"2–4%","effect":"Immune-related colitis"},{"rate":"15–20%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 inhibitors bind to the PD-1 receptor on T cells, blocking interaction with PD-L1/PD-L2 ligands expressed on tumor cells and immune cells. This releases the 'brakes' on anti-tumor immunity, restoring T cell proliferation, activation, and cytotoxic function. A full course typically involves multiple doses administered over several months to achieve sustained immune activation.","oneSentence":"PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:34.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Non-small cell lung cancer"},{"name":"Renal cell carcinoma"},{"name":"Hodgkin lymphoma"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07328841","phase":"PHASE3","title":"Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-18","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":456}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Full course of PD-1blockades","genericName":"Full course of PD-1blockades","companyName":"Ming-Yuan Chen","companyId":"ming-yuan-chen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PD-1 blockade inhibits the programmed death-1 checkpoint, allowing T cells to recognize and attack cancer cells. Used for Metastatic melanoma, Non-small cell lung cancer, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}